Search Result

Results for "

bowel

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (25) Adenosine Receptor (2) Adrenergic Receptor (3) Akt (3) Aminopeptidase (1) AMPK (3) Antibiotic (4) Apical Sodium-Dependent Bile Acid Transporter (3) Apoptosis (14) Aurora Kinase (4) Bacterial (7) Calcium Channel (5) Cathepsin (1) CCR (5) CDK (2) CFTR (1) Chloride Channel (1) COX (1) CRFR (1) CX3CR1 (1) CXCR (5) Dihydroorotate Dehydrogenase (3) Dopamine Transporter (2) Drug Derivative (1) Drug Metabolite (1) Dynamin (1) E1/E2/E3 Enzyme (1) Endogenous Metabolite (5) Epigenetic Reader Domain (1) ERK (2) Estrogen Receptor/ERR (1) Fluorescent Dye (1) FXR (3) GCGR (3) GLP Receptor (3) Glucocorticoid Receptor (2) Glutathione S-transferase (1) GPR109A (1) GPR35 (1) Guanylate Cyclase (5) HIF/HIF Prolyl-Hydroxylase (2) Histamine Receptor (1) HIV (2) IFNAR (3) IKK (1) Indoleamine 2,3-Dioxygenase (IDO) (4) Integrin (2) Interleukin Related (14) IRAK (2) Isotope-Labeled Compounds (4) JAK (9) Leukotriene Receptor (4) Lipoxygenase (2) mAChR (18) METTL3 (2) Motilin Receptor (1) Na+/K+ ATPase (2) Neurokinin Receptor (4) NF-κB (6) NO Synthase (3) NOD-like Receptor (NLR) (6) Oct3/4 (2) Opioid Receptor (4) Orphan Receptor (2) P2Y Receptor (1) p38 MAPK (1) Parasite (4) Phosphodiesterase (PDE) (4) PIKfyve (1) Potassium Channel (4) Prostaglandin Receptor (1) Proton Pump (2) Pyroptosis (1) Reactive Oxygen Species (3) RET (2) RIP kinase (4) ROR (2) Sodium Channel (2) STAT (2) STING (1) TNF Receptor (9) Toll-like Receptor (TLR) (1) TRP Channel (1) Virus Protease (4)
By Research Areas:	Cancer (30) Cardiovascular Disease (2) Endocrinology (8) Infection (11) Inflammation/Immunology (126) Metabolic Disease (45) Neurological Disease (45)

By Targets:

5-HT Receptor (25)

Adenosine Receptor (2)

Adrenergic Receptor (3)

Akt (3)

Aminopeptidase (1)

AMPK (3)

Antibiotic (4)

Apical Sodium-Dependent Bile Acid Transporter (3)

Apoptosis (14)

Aurora Kinase (4)

Bacterial (7)

Calcium Channel (5)

Cathepsin (1)

CCR (5)

CDK (2)

CFTR (1)

Chloride Channel (1)

COX (1)

CRFR (1)

CX3CR1 (1)

CXCR (5)

Dihydroorotate Dehydrogenase (3)

Dopamine Transporter (2)

Drug Derivative (1)

Drug Metabolite (1)

Dynamin (1)

E1/E2/E3 Enzyme (1)

Endogenous Metabolite (5)

Epigenetic Reader Domain (1)

ERK (2)

Estrogen Receptor/ERR (1)

Fluorescent Dye (1)

FXR (3)

GCGR (3)

GLP Receptor (3)

Glucocorticoid Receptor (2)

Glutathione S-transferase (1)

GPR109A (1)

GPR35 (1)

Guanylate Cyclase (5)

HIF/HIF Prolyl-Hydroxylase (2)

Histamine Receptor (1)

HIV (2)

IFNAR (3)

IKK (1)

Indoleamine 2,3-Dioxygenase (IDO) (4)

Integrin (2)

Interleukin Related (14)

IRAK (2)

Isotope-Labeled Compounds (4)

JAK (9)

Leukotriene Receptor (4)

Lipoxygenase (2)

mAChR (18)

METTL3 (2)

Motilin Receptor (1)

Na+/K+ ATPase (2)

Neurokinin Receptor (4)

NF-κB (6)

NO Synthase (3)

NOD-like Receptor (NLR) (6)

Oct3/4 (2)

Opioid Receptor (4)

Orphan Receptor (2)

P2Y Receptor (1)

p38 MAPK (1)

Parasite (4)

Phosphodiesterase (PDE) (4)

PIKfyve (1)

Potassium Channel (4)

Prostaglandin Receptor (1)

Proton Pump (2)

Pyroptosis (1)

Reactive Oxygen Species (3)

RET (2)

RIP kinase (4)

ROR (2)

Sodium Channel (2)

STAT (2)

STING (1)

TNF Receptor (9)

Toll-like Receptor (TLR) (1)

TRP Channel (1)

Virus Protease (4)

By Research Areas:

Cancer (30)

Cardiovascular Disease (2)

Endocrinology (8)

Infection (11)

Inflammation/Immunology (126)

Metabolic Disease (45)

Neurological Disease (45)

200

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-137789

Tazofelone LY 213829	COX	Cancer
Tazofelone (LY 213829) is a cyclooxygenase-II (COX-II) inhibitor. Tazofelone transform into sulfoxide and quinol metabolites is primarily mediated by CYP3A. Tazofelone can be used for the research of inflammatory bowel disease .

HY-16640

TCJL37	JAK	Inflammation/Immunology
TCJL37 is a potent, selective, and orally bioavailable TYK2 inhibitor with a K_i of 1.6 nM. TCJL37 can be used for the research of inflammatory bowel diseases (IBD) .

HY-107649

Zamifenacin fumarate UK-76654 fumarate	mAChR	Metabolic Disease
Zamifenacin fumarate (UK-76654 fumarate) is a potent gut-selective muscarinic M3 receptor antagonist. Zamifenacin significantly reduces colonic motility in irritable bowel syndrome .

HY-123337

Zamifenacin UK-76654	mAChR	Metabolic Disease
Zamifenacin (UK-76654) is a potent gut-selective muscarinic M3 receptor antagonist. Zamifenacin significantly reduces colonic motility in irritable bowel syndrome .

HY-111613

Pinaverium bromide 4 Publications Verification	Calcium Channel	Cancer
Pinaverium bromide is an L-type calcium channel blocker with selectivity for the gastrointestinal tract, effectively relieves pain, diarrhea and intestinal discomfort, provides good therapeutic efficacies without significant adverse effects on Irritable bowel syndrome (IBS) patients .

HY-115744

Mercaptoethylguanidine (MEG) (dihydrobromide)	NO Synthase	Inflammation/Immunology
Mercaptoethylguanidine (MEG) dihydrobromide is selective inhibitor of the inducible nitric oxide synthase and peroxynitrite scavenger. Mercaptoethylguanidine (MEG) dihydrobromide has the potential for inflammatory bowel diseases research.

HY-107015A

Prednisolone metazoate sodium Predfoam; ATL 2502	Glucocorticoid Receptor	Inflammation/Immunology
Prednisolone metazoate sodium (ATL 2502) can be used for study of inflammatory bowel disease, ulcerative colitis, and GI disorders .

HY-158404

METTL3-IN-8	METTL3	Inflammation/Immunology
METTL3-IN-8 (7460-0250) is a potent METTL3 inhibitor. METTL3-IN-8 strongly ameliorates DSS-induced colitis. METTL3-IN-8 can be used Inflammatory bowel disease (IBD) research .

HY-142834

RORγt/DHODH-IN-2	ROR Dihydroorotate Dehydrogenase	Inflammation/Immunology
RORγt/DHODH-IN-2 (compound 1) is a potent dual RORγt/DHODH inhibitor. RORγt/DHODH-IN-2 can be used for inflammatory bowel disease (IBD) research .

HY-118795

SC-22716	Aminopeptidase	Inflammation/Immunology
SC-22716 is a potent, competitive, reversible inhibitor of human LTA₄ hydrolase, with an IC₅₀ of 0.20 µM. SC-22716 has potential for the research of inflammatory bowel disease (IBD) and psoriasis .

HY-158403

METTL3-IN-7	METTL3	Inflammation/Immunology
METTL3-IN-7 (F039-0002) is a potent METTL3 inhibitor. METTL3-IN-7 strongly ameliorates dextran sodium sulfate (DSS)-induced colitis. METTL3-IN-7 can be used Inflammatory bowel disease (IBD) research .

HY-147527

CDK8-IN-5	CDK	Inflammation/Immunology
CDK8-IN-5 is a potent CDK8 inhibitor with an IC₅₀ of 72 nM. CDK8-IN-5 shows anti-inflammatory activities with 43% IL-10 enhancement rate. CDK8-IN-5 has the potential for the research of inflammatory bowel disease .

HY-151952

NLRP3-IN-12	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-12 is a specific NLRP3 inflammasome inhibitor. NLRP3-IN-12 reduces the release of IL-1β by targeting the NLRP3 protein, with an IC₅₀ of 0.45 μM. NLRP3-IN-12 can be used for the research of inflammatory bowel disease .

HY-108171A

Hexocyclium methylsulfate	mAChR	Inflammation/Immunology
Hexocyclium methylsulfate is a potent mAChR antagonist with pK_i values of 8.9, 7.7, 8.4, 8.8 for M1, M2, M3, and M4 subtype, respectively. Hexocyclium methylsulfate has the potential for the research of duodenal ulcer and irritable bowel syndrome .

HY-B0499A

Otilonium bromide 2 Publications Verification Octylonium bromide; SP63	mAChR	Neurological Disease
Otilonium bromide (OB) is an orally active mAChR inhibitor and smooth muscle relaxant which can interfere with the mobilization of calcium in intestinal smooth muscle, OB can be used for research of irritable bowel syndrome .

HY-E70288

ST6 Sialyltransferase 6 ST6GALNAC6	Others	Inflammation/Immunology
ST6 Sialyltransferase 6 (ST6GALNAC6) belongs to the salivary transferase family, which modifies proteins and ceramides on the cell surface, thereby altering intercellular or extracellular matrix interactions. ST6 Sialyltransferase 6 can be used in the study of inflammatory bowel disease (IBD) .

HY-168591

CTSC-IN-1	Cathepsin	Cancer
CTSC-IN-1 (B22) is a CTSC inhibitor. CTSC-IN-1 inhibits CTSC activity by binding to S2 pocket and S1 site. CTSC-IN-1 can be used in the study inflammatory bowel disease .

HY-19667A

BMS-561392 formate 1 Publications Verification DPC 333 formate	TNF Receptor	Inflammation/Immunology
BMS-561392 formate is the formate form of BMS-561392 (HY-19667). BMS-561392 is a TNF alpha-converting enzyme (TACE) inhibitor. BMS-561392 is also an ADAM17 blocker. BMS-561392 can be used for research of inflammatory bowel disease .

HY-14147

Renzapride BRL 24924	5-HT Receptor	Metabolic Disease
Renzapride (BRL 24924), a substituted benzamide, is a full 5-HT₄ receptor agonist with a K_i value of 115 nM. Renzapride (BRL 24924) is also a 5HT2b and 5HT3 receptor antagonist . Renzapride could be used for constipation predominant irritable bowel syndrome (C-IBS) study .

HY-111613R

Pinaverium bromide (Standard)	Calcium Channel	Cancer
Pinaverium bromide (Standard) is the analytical standard of Pinaverium bromide. This product is intended for research and analytical applications. Pinaverium bromide is an L-type calcium channel blocker with selectivity for the gastrointestinal tract, effectively relieves pain, diarrhea and intestinal discomfort, provides good therapeutic efficacies without significant adverse effects on Irritable bowel syndrome (IBS) patients .

HY-148531

PF-07054894	CCR	Inflammation/Immunology
PF-07054894 is an orally active and potent C-C Chemoattractant Cytokine (Chemokine) Receptor 6 (CCR6) antagonist that blocks CCR6-mediated chemotaxis with an IC₅₀ value of 5.7 nM in vitro. PF-07054894 targets G protein-coupled receptor (GPCR). PF-07054894 can be used in research of inflammatory bowel disease .

HY-100278

AKP-001	p38 MAPK	Inflammation/Immunology
AKP-001 is an inhibitor of p38 mitogen-activated protein kinase (p38 MAPK). AKP-001 can inhibit the production of inflammatory cytokines and can be used for research in rheumatoid arthritis and inflammatory bowel disease .

HY-15707

NS6180 1 Publications Verification	Potassium Channel	Inflammation/Immunology
NS6180 is a new orally active KCa3.1 channel inhibitor. NS6180 inhibits cloned human KCa3.1 channels with an IC₅₀value of 9 nM. NS6180 can be used for the research of inflammatory bowel disease (IBD) .

HY-168846

CDK8/19-IN-3	CDK	Inflammation/Immunology
CDK8/19-IN-3 (compound 3-7) is a potent and selective CDK8 and CDK19 inhibitor. CDK8/19-IN-3 upregulates IL-10 levels. CDK8/19-IN-3 has the potential for the research of inflammatory bowel disease (IBD) .

HY-P3291

Dapiglutide 1 Publications Verification ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .

HY-P1142

GLP-2(rat)	Apoptosis	Others
GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR) .

HY-P3499

Dolcanatide	Guanylate Cyclase	Inflammation/Immunology
Dolcanatide is an orally active GC-C (guanylate cyclase-C) agonist. Dolcanatide shows laxative, anti-nociceptive and anti-inflammatory activity. Dolcanatide can be used in inflammatory bowel disease research .

HY-N2549

(±)-Abscisic acid (±)-ABA	Calcium Channel	Metabolic Disease Inflammation/Immunology
(±)-Abscisic acid ((±)-ABA) is an orally active phytohormone. (±)-Abscisic acid induces Ca ²⁺ channel opening to facilitate the influx of calcium ions and modulates stomatal movement. (±)-Abscisic acid shows anti-inflammatory activity and has the potential for the research of inflammatory bowel disease (IBD) .

HY-161757

Anti-inflammatory agent 86	Drug Derivative	Inflammation/Immunology
Anti-inflammatory agent 86 is a Chrysin (HY-14589) derivative with anti-inflammatory effects. Anti-inflammatory agent 86 inhibits monocyte adhesion to colon epithelium induced by TNF-α, with an IC₅₀ of 4.71 μM. Anti-inflammatory agent 86 has the potential for the inflammatory bowel disease (IBD) research .

HY-B0499AR

Otilonium (bromide) (Standard)	mAChR	Neurological Disease
Otilonium (bromide) (Standard) is the analytical standard of Otilonium (bromide). This product is intended for research and analytical applications. Otilonium bromide (OB) is an orally active mAChR inhibitor and smooth muscle relaxant which can interfere with the mobilization of calcium in intestinal smooth muscle, OB can be used for research of irritable bowel syndrome .

HY-P1142A

GLP-2(rat) TFA	Apoptosis	Others
GLP-2(rat) TFA is an intestinal growth factor. GLP-2(rat) TFA stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) TFA enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR) .

HY-12820

Sibofimloc 2 Publications Verification Antibiotic-202	Bacterial Antibiotic	Infection
Sibofimloc (Antibiotic-202) is a first-in-class, gut-restricted, orally active FimH adhesion inhibitor extracted from patent WO2014100158A1, Compound Example 202. Sibofimloc has anti-bacterial infective activity. Sibofimloc is developed for inflammatory bowel disease (IBD) .

HY-18263

Elubrixin hydrochloride SB-656933 hydrochloride	CXCR Interleukin Related	Inflammation/Immunology
Elubrixin (SB-656933) hydrochloride is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin hydrochloride inhibits neutrophil CD11b upregulation (IC₅₀ of 260.7 nM) and shape change (IC₅₀ of 310.5 nM). Elubrixin hydrochloride has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation .

HY-18263C

Elubrixin tosylate SB-656933 tosylate	CXCR Interleukin Related	Inflammation/Immunology
Elubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin tosylate inhibits neutrophil CD11b upregulation (IC₅₀ of 260.7 nM) and shape change (IC₅₀ of 310.5 nM). Elubrixin tosylate has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation .

HY-18263A

Elubrixin SB-656933	CXCR Interleukin Related	Inflammation/Immunology
Elubrixin (SB-656933) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin inhibits neutrophil CD11b upregulation (IC₅₀ of 260.7 nM) and shape change (IC₅₀ of 310.5 nM). Elubrixin has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation .

HY-100459

GSK3179106 4 Publications Verification	RET	Metabolic Disease Inflammation/Immunology
GSK3179106 is an orally active and selective RET kinase inhibitor with IC₅₀s of 0.4 nM, 0.2 nM for human RET and rat RET, respectively. GSK3179106 has the potential for irritable bowel syndrome (IBS) through the attenuation of post-inflammatory and stress-induced visceral hypersensitivity .

HY-P2221B

Glepaglutide acetate 1 Publications Verification ZP1848 acetate	GCGR	Inflammation/Immunology
Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .

HY-P2221

Glepaglutide ZP1848	GCGR	Inflammation/Immunology
Glepaglutide (ZP1848), a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide reduces faecal output and increases intestinal absorption. Glepaglutide alleviates small intestinal inflammation. Glepaglutide can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .

HY-161735

CXCR4-IN-3	CXCR	Inflammation/Immunology
CXCR4-IN-3 (compound XVI) is an orally active and potent inhibitor targeting the inflammation-related receptor CXCR4, with an IC₅₀ of 3.2 nM. CXCR4-IN-3 exhibits potent antichemotactic activity, at 79.19±2.33% inhibition. CXCR4-IN-3 shows anti-inflammatory activity. CXCR4-IN-3 can be used for IBD (inflammatory bowel disease) research .

HY-151174

PDE4-IN-12	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-12 is a potent pan-PDE4 inhibitor, with IC₅₀s of 3.5 and 15 nM for PDE4 and PDE7, respectively (SI=2.71 and 4.27, respectively). PDE4-IN-12 shows well tolerated, can be used in study of inflammatory bowel diseases (IBDs) .

HY-14147A

(S)-Renzapride (S)-BRL 24924	5-HT Receptor	Metabolic Disease
(S)-Renzapride ((S)-BRL 24924) is the isomer of HY-14147 Renzapride. Renzapride is a 5-HT₄ receptor agonist with a K_i value of 115 nM. Renzapride also is a 5HT2b and 5HT3 receptor antagonist. Renzapride can be used for constipation predominant irritable bowel syndrome (C-IBS) study .

HY-W778340

16α-Hydroxy-11-keto prednisolone	Drug Metabolite Glucocorticoid Receptor	Inflammation/Immunology Cancer
16α-Hydroxy-11-keto prednisolone (compound M-X) is a metabolite of Budesonide (HY-13580). Budesonide, an inhaled glucocortical steroid, is an orally active glucocorticoid receptor agonist. Budesonide is a widely used for study of asthma, rhinitis, and inflammatory bowel disease .

HY-155680

BET BD2-IN-1	Epigenetic Reader Domain	Inflammation/Immunology
BET BD2-IN-1 (compound 45) is a potent and selective inhibitor of BET BD2 (IC₅₀=1.6 nM). BET BD2-IN-1 inhibits the differentiation of Th17 cells by decreasing the activation of STAT3 and NF-κB. BET BD2-IN-1 is used in psoriasis and inflammatory bowel disease (IBD) research .

HY-P99184

Abrilumab	Integrin	Infection Inflammation/Immunology Cancer
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .

HY-P99486

Briakinumab ABT-874	Interleukin Related	Inflammation/Immunology
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .

HY-A0274

Ramosetron YM060 free base	5-HT Receptor	Others
Ramosetron (YM060 free base) is an orally active 5-HT₃ antagonist that improves dysphoria, interference with activity and food avoidance. Ramosetron is promising for research of irritable bowel syndrome with diarrhea .

HY-162734

BRD5075	Interleukin Related	Inflammation/Immunology
BRD5075 is a potent GPR65 activator. BRD5075 induces GPR65-dependent cAMP production. BRD5075 decreases the gene expression of IL-1, IL-2, TNF, and chemokine. BRD5075 has the potential for the research of multiple sclerosis and inflammatory bowel disease (IBD) .

HY-107384

Asimadoline EMD-61753	Opioid Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology
Asimadoline (EMD-61753) is an orally active, selective and peripherally active κ-opioid agonist with IC₅₀s of 5.6 nM (guinea pig) and 1.2 nM (human recombinant). Asimadoline has low permeability across the blood brain barrier and has peripheral anti-inflammatory actions. Asimadoline ameliorates allodynia in diabetic rats and has the potential for irritable bowel syndrome (IBS) .

HY-107384A

Asimadoline hydrochloride EMD-61753 hydrochloride	Opioid Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology
Asimadoline (EMD-61753) hydrochloride is an orally active, selective and peripherally active κ-opioid agonist with IC₅₀s of 5.6 nM (guinea pig) and 1.2 nM (human recombinant). Asimadoline hydrochloride has low permeability across the blood brain barrier and has peripheral anti-inflammatory actions. Asimadoline hydrochloride ameliorates allodynia in diabetic rats and has the potential for irritable bowel syndrome (IBS) .

HY-P5782

δ-Theraphotoxin-Hm1a toxin	Sodium Channel	Neurological Disease
δ-Theraphotoxin-Hm1a toxin is a selective Na_v1.1 activator. δ-Theraphotoxin-Hm1a toxin elicits pain and touch sensitivity. δ-Theraphotoxin-Hm1a toxin can be used for the research of irritable bowel syndrome .

Cat. No.	Product Name

HY-L078

Gut Microbial Metabolite Library

504 compounds

Accumulating evidence has revealed that intestinal microbiota play an important role in human health and disease, including cardiovascular diseases, inflammatory bowel disease, diabetes, obesity, cancer, and depression, etc. Changes in the composition of gut microbiota associated with disease, referred to as dysbiosis, have been linked to pathologies. Indeed, the gut microbiome functions like an endocrine organ, generating bioactive metabolites which play important roles in human metabolism, health, and disease. Gut microbiome has become a novel therapeutic target for many diseases. Analysis and identification of gut microbial metabolite will contribute to the development of therapeutic methods.

In order to meet the need of gut microbiome research, MCE carefully selected a unique collection of 504 gut microbial metabolites. MCE gut microbial metabolite library is a powerful tool for gut microbiome research and gut microbiome -related drug discovery.

HY-L103

Anti-Colorectal Cancer Compound Library

1,884 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 1,884 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

HY-L014

NF-κB Signaling Compound Library

1,048 compounds

Nuclear factor-κB (NF-κB)/Rel proteins include NF-κB2 p52/p100, NF-κB1 p50/p105, c-Rel, RelA/p65, and RelB. These proteins function as dimeric transcription factors that regulate the expression of genes and influence a broad range of biological processes including innate and adaptive immunity, inflammation, stress responses, B-cell development, and lymphoid organogenesis. NF-κB plays a key role in regulating the immune response to infection. In addition, activation of the NF-κB pathway is involved in the pathogenesis of chronic inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development.

MCE owns a unique collection of 1,048 small molecule compounds that can be used in the research of NF-κB signaling pathway or high throughput screening (HTS) related drug discovery.

Cat. No.	Product Name	Type

HY-123630

Allura Red AC

FD&C RED NO. 40; CI 16035

Dyes

Allura Red AC is a food colorant, appearing as a deep red water-soluble powder or granules, used in various applications such as beverages, syrups, candies, and cereals. Allura Red AC can statically quench the intrinsic fluorescence of HSA. Additionally, Allura Red AC is a 5-hydroxytryptamine (5-HT) pathway-associated pro-inflammatory agent, capable of exacerbating experimental colitis. Allura Red AC holds potential for research in inflammatory bowel disease (IBD), intestinal barrier function, and food additive safety .

HY-123630R

Allura Red AC (Standard)

Dyes

Allura Red AC (Standard) is an analytical standard of Allura Red AC. This product is intended for research and analytical applications. Allura Red AC is a food colorant, appearing as a deep red water-soluble powder or granules, used in various applications such as beverages, syrups, candies, and cereals. Allura Red AC can statically quench the intrinsic fluorescence of HSA. Additionally, Allura Red AC is a 5-hydroxytryptamine (5-HT) pathway-associated pro-inflammatory agent, capable of exacerbating experimental colitis. Allura Red AC holds potential for research in inflammatory bowel disease (IBD), intestinal barrier function, and food additive safety .

Cat. No.	Product Name	Target	Research Area

HY-P3291

Dapiglutide 1 Publications Verification ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .

HY-P1142

GLP-2(rat)	Apoptosis	Others
GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR) .

HY-P3499

Dolcanatide	Guanylate Cyclase	Inflammation/Immunology
Dolcanatide is an orally active GC-C (guanylate cyclase-C) agonist. Dolcanatide shows laxative, anti-nociceptive and anti-inflammatory activity. Dolcanatide can be used in inflammatory bowel disease research .

HY-P2221B

Glepaglutide acetate 1 Publications Verification ZP1848 acetate	GCGR	Inflammation/Immunology
Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .

HY-P3507

Dalazatide ShK-186	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-P1142A

GLP-2(rat) TFA	Apoptosis	Others
GLP-2(rat) TFA is an intestinal growth factor. GLP-2(rat) TFA stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) TFA enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR) .

HY-P2221

Glepaglutide ZP1848	GCGR	Inflammation/Immunology
Glepaglutide (ZP1848), a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide reduces faecal output and increases intestinal absorption. Glepaglutide alleviates small intestinal inflammation. Glepaglutide can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .

HY-P5782

δ-Theraphotoxin-Hm1a toxin	Sodium Channel	Neurological Disease
δ-Theraphotoxin-Hm1a toxin is a selective Na_v1.1 activator. δ-Theraphotoxin-Hm1a toxin elicits pain and touch sensitivity. δ-Theraphotoxin-Hm1a toxin can be used for the research of irritable bowel syndrome .

HY-P1142S

GLP-2(rat) (Ala-13C3,15N)	Isotope-Labeled Compounds	Others
GLP-2(rat) (Ala- ¹³C3, ¹⁵N) is ¹³C and ¹⁵N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).

HY-P1142S1

GLP-2(rat) (Ala-13C3,15N) TFA	Isotope-Labeled Compounds Apoptosis	Others
GLP-2(rat) (Ala- ¹³C3, ¹⁵N) TFA is ¹³C and ¹⁵N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).

HY-P3507A

Dalazatide TFA ShK-186 TFA	Potassium Channel	Metabolic Disease Inflammation/Immunology
Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease .

HY-P10587

Icotrokinra JNJ-77242113; JNJ-2113; PN-235	Interleukin Related STAT	Inflammation/Immunology
Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC₅₀=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC₅₀ of 18.4 pM. In addition, Icotrokinra exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease .

HY-17584

Linaclotide 2 Publications Verification	Guanylate Cyclase	Cancer
Linaclotide is a potent and selective guanylate cyclase C agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.

HY-P3282

MM 419447	Guanylate Cyclase	Metabolic Disease
MM 419447, a linaclotide metabolite, is a guanylate cyclase-C agonist. MM 419447 has the potential for the research of the irritable bowel syndrome with constipation (IBS-C) .

HY-17584A

Linaclotide acetate	Guanylate Cyclase	Cancer
Linaclotide acetate is a potent and selective guanylate cyclase C agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.

HY-13545B

ABT-510 acetate	Apoptosis	Inflammation/Immunology Cancer
ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-13545

ABT-510	Apoptosis	Inflammation/Immunology Cancer
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-17584R

Linaclotide (Standard)	Guanylate Cyclase	Cancer
Linaclotide (Standard) is the analytical standard of Linaclotide. This product is intended for research and analytical applications. Linaclotide is a potent and selective guanylate cyclase C agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.

HY-P1714

Apraglutide FE 203799	GLP Receptor	Metabolic Disease
Apraglutide (FE 203799), a synthetic 33-amino-acid peptide and a long-acting GLP-2 analogue, enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum .

HY-P1714A

Apraglutide TFA FE 203799 TFA	GLP Receptor	Metabolic Disease
Apraglutide TFA (FE 203799 TFA), a synthetic 33-amino-acid peptide and a long-acting GLP-2 analogue, enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum .

HY-P10839

NBD peptide	NF-κB	Inflammation/Immunology
NBD peptide inhibits NF-κB signaling pathway through inhibition of the NEMO-IKK complex combination. NBD peptide exhibits anti-inflammatory efficacy through block of pro-inflammatory cytokines production. NBD peptide exhibits immunosuppressive activity through regulation of immune cells. NBD peptide enhances its transmembrane ability by combining with cell-penetrating peptide HIV-TAT .

HY-P10842

d-GLP-2 E33A	GLP Receptor Akt	Metabolic Disease Inflammation/Immunology
d-GLP-2 E33A is an agonist for the glucagon-like peptide 2 receptor (GLP-2R) with an EC₅₀ of 414 nM. d-GLP-2 E33A can activate GLP-2R and increase the phosphorylation of AKT, but has no stimulative effect on GLP-1R. d-GLP-2 E33A can be used in the study of diseases such as intestinal malabsorption and inflammatory bowel diseases .

HY-P10081

CTP-NBD	NF-κB	Inflammation/Immunology
CTP-NBD is a cell permeable specific NFκB peptide inhibitor. CTP-NBD could be used in colitis study

HY-P10368

P110 heptapeptide	Dynamin	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
P110 heptapeptide, a peptide inhibitor of Drp1-Fis1 interaction, reduces pathology in numerous models of neurodegeneration, ischemia, and sepsis without blocking the physiological functions of Drp1 .

Cat. No.	Product Name	Target	Research Area

HY-P99184

Abrilumab	Integrin	Infection Inflammation/Immunology Cancer
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .

HY-P99486

Briakinumab ABT-874	Interleukin Related	Inflammation/Immunology
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .

HY-P9984

Etrolizumab 2 Publications Verification rhuMAb Beta7; RG7413; PRO145223	Integrin	Cancer
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with K_i values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .

HY-P990876

Afimkibart PF-06480605; RVT-3101	TNF Receptor	Inflammation/Immunology
Afimkibart (PF-06480605) is a human IgG1 monoclonal antibody targeting tumor necrosis factor-like ligand 1A (TL1A). Afimkibart can be used in the research of inflammatory bowel disease .

HY-P99389

Tesnatilimab	Inhibitory Antibodies	Inflammation/Immunology
Tesnatilimab is a human IgG4 monoclonal antibody that acts on the immune activating receptor NKG2D and has potential immunomodulatory and anti-inflammatory activity. Tesnatilimab can be used in the study of inflammatory bowel disease (IBD) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2549

(±)-Abscisic acid (±)-ABA	Structural Classification Natural Products other families Classification of Application Fields Source classification Metabolic Disease Abscisic acid Plants Phytohormone Disease Research Fields Agricultural Research	Calcium Channel
(±)-Abscisic acid ((±)-ABA) is an orally active phytohormone. (±)-Abscisic acid induces Ca ²⁺ channel opening to facilitate the influx of calcium ions and modulates stomatal movement. (±)-Abscisic acid shows anti-inflammatory activity and has the potential for the research of inflammatory bowel disease (IBD) .

HY-B2134

Casanthranol	Structural Classification Natural Products other families Classification of Application Fields Source classification Metabolic Disease Plants Disease Research Fields	Others
Casanthranol is a concentrated mixture of anthranol glycosides from cascara sagrada (dried bark of Rhamnus p.) and used as a laxative in constipation and various medical conditions, stimulant laxative Casanthranol encourages bowel movements by acting on the intestinal wall to increase muscle contractions .

HY-113259

7α-Hydroxy-4-cholesten-3-one	Structural Classification Microorganisms Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .

HY-N0110

Palmatine chloride Maximum Cited Publications 6 Publications Verification	Structural Classification Alkaloids Phellodendron amurense Rupr. Classification of Application Fields Rutaceae Plants Isoquinoline Alkaloids Disease Research Fields Cancer	mAChR Indoleamine 2,3-Dioxygenase (IDO) Virus Protease Aurora Kinase Apoptosis Bacterial Parasite
Palmatine chloride is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC₅₀s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine chloride can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC₅₀ of 96 μM. Palmatine chloride shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities .

HY-N0110B

Palmatine hydroxide Maximum Cited Publications 6 Publications Verification	Alkaloids Phellodendron amurense Rupr. Other Alkaloids Source classification Rutaceae Plants	mAChR Indoleamine 2,3-Dioxygenase (IDO) Virus Protease Aurora Kinase Apoptosis Bacterial Parasite
Palmatine hydroxide is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC₅₀s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine hydroxide can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC₅₀ of 96 μM. Palmatine hydroxide shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities .

HY-113259R

7α-Hydroxy-4-cholesten-3-one (Standard)	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
7α-Hydroxy-4-cholesten-3-one (Standard) is the analytical standard of 7α-Hydroxy-4-cholesten-3-one. This product is intended for research and analytical applications. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .

HY-N0110R

Palmatine chloride (Standard)	Structural Classification Alkaloids Phellodendron amurense Rupr. Classification of Application Fields Source classification Rutaceae Plants Isoquinoline Alkaloids Disease Research Fields Cancer	Apoptosis Virus Protease Indoleamine 2,3-Dioxygenase (IDO) Parasite Bacterial Aurora Kinase mAChR
Palmatine (chloride) (Standard) is the analytical standard of Palmatine (chloride). This product is intended for research and analytical applications. Palmatine chloride is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC₅₀s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine chloride can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC₅₀ of 96 μM. Palmatine chloride shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities .

HY-N0110A

Palmatine	Alkaloids Structural Classification Phellodendron amurense Rupr. Classification of Application Fields Source classification Rutaceae Plants Isoquinoline Alkaloids Inflammation/Immunology Disease Research Fields	mAChR Indoleamine 2,3-Dioxygenase (IDO) Virus Protease Aurora Kinase Apoptosis Bacterial Parasite
Palmatine is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC₅₀s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC₅₀ of 96 μM. Palmatine shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities .

Cat. No.	Product Name	Chemical Structure

HY-113259S

7α-Hydroxy-4-cholesten-3-one-d7

7α-Hydroxy-4-cholesten-3-one-d₇ is the deuterium labeled 7α-Hydroxy-4-cholesten-3-one. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1[1][2].

HY-P1142S

GLP-2(rat) (Ala-13C3,15N)
GLP-2(rat) (Ala- ¹³C3, ¹⁵N) is ¹³C and ¹⁵N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).

HY-P1142S1

GLP-2(rat) (Ala-13C3,15N) TFA
GLP-2(rat) (Ala- ¹³C3, ¹⁵N) TFA is ¹³C and ¹⁵N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).

HY-17623S

Tegoprazan-d6

Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC₅₀ values ranging from 0.29-0.52 μM for porcine, canine, and human H ⁺/K ⁺-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .

HY-14153S

Tegaserod-d11

Tegaserod-d₁₁ is deuterated labeled Tegaserod (HY-14153). Tegaserod is an orally active serotonin receptor 4 (HTR4; 5-HT₄R) agonist and a 5-HT_2B receptor antagonist. Tegaserod has pK_is of 7.5, 8.4 and 7.0 for human recombinant 5-HT_2A, 5-HT_2B and 5-HT_2C receptors, respectively. Tegaserod causes tumor cell apoptosis, blunts PI3K/Akt/mTOR signaling and decreases S6 phosphorylation. Tegaserod has anti-tumor activity and has the potential for irritable bowel syndrome (IBS) research .

HY-111613S

Pinaverium bromide-d4
Pinaverium bromide-d₄ is deuterium labeled Pinaverium bromide. Pinaverium bromide is an L-type calcium channel blocker with selectivity for the gastrointestinal tract, effectively relieves pain, diarrhea and intestinal discomfort, provides good therapeutic efficacies without significant adverse effects on Irritable bowel syndrome (IBS) patients[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks